Immunosuppression (Treatment)

Pegylated Blood Products May Help Treat Immunosuppressed Patients

Published in Blood Weekly, October 18th, 1999

The use of blood products modified with methoxy(polyethylene glycol) (mPEG) may be helpful in treating both immunosuppressed and chronically transfused patients.

Previously, Kari L Murad, Albany Medical College, Albany, New York, and colleagues reported that the modification of red cell (RBC) membranes with nonimmunogenic materials, such as mPEG, could yield antigenically silent (stealth) cells. The stealth cells showed decreased/absent antisera-mediated agglutination, antibody binding, and decreased immunogenicity. The modification had no negative effects on normal cell structure, function, or viability.

Based on their earlier findings, Murad et...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (1999-10-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry